| Business Summary | | Implant
Sciences
Corporation
has
developed
core
technologies
using
ion
implantation
and
thin
film
coatings
for
medical
device
applications
and
has
proprietary
processes
and
equipment
for
the
manufacture
of
medical
radiation
therapeutic
devices.
The
Company
is
applying
this
technology
to
manufacture
radioactive
prostate
seeds
using
a
dry
fabrication
process
that
it
believes
will
be
more
cost-effective
and
less
hazardous
than
conventional
processes
that
use
radioactive
wet
chemistry. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | IMX
is
a
provider
of
patented
and
proprietary
surface
modification
services
to
the
medical
device
and
semiconductor
industries.
For
the
nine
months
ended
3/31/01,
total
revenues
increased
2%
to
$3.1
million.
Net
loss
increased
50%
to
$2.4
million.
Revenues
reflect
sales
recognized
from
the
new
I-Plant
seed.
Net
loss
reflects
increased
S/G/A
expenses
due
to
the
write-off
of
deferred
financing
costs
and
additional
personnel. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Anthony Armini, 62 Pres,
CEO, Chairman | $174K | David Volpe CFO | -- | Stephen Bunker, 57 VP,
Chief Scientist, Director | 125K | Alan Lucas, 44 VP
of Bus. Devel., Marketing and Sales | 175K | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|